BioNTech presents promising late-stage lung cancer trial data at ELCC 2026, advancing new treatment options.

Head and neck squamous cell carcinoma market to grow 10.5% CAGR through 2036 with new immunotherapies.

The head and neck squamous cell carcinoma (HNSCC) market is projected to grow at a 10.5% CAGR from 2026 to 2036, driven by rising cancer incidence and new immunotherapy launches. Key emerging therapies from companies like Johnson & Johnson, BioNTech,...